Search for Clinical Trial Results
Coagulation Protein Disorders - 25 Studies Found
Status | Study |
Completed |
Study Name: Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Study) Condition:
Interventions: |
Enrolling by invitation |
Study Name: A Study of ProMetic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia Condition: Hypoplasminogenemia Date: 2016-02-12 Interventions: Biological: Plasminogen (human) intravenous ProMetic Plasminogen(human) intravenous |
Completed |
Study Name: A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency Condition:
Date: 2014-12-04 Interventions: Biological: Plasminogen (Human) Intravenous Plasma-derived purified plasminogen formulated for intraveno |
Recruiting |
Study Name: Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products Condition: Hemophilia A Date: 2016-11-24 Interventions:
|
Recruiting |
Study Name: A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B Condition:
Date: 2017-02-14 Interventions:
|
Recruiting |
Study Name: A Gene Transfer Study for Hemophilia A Condition: Hemophilia A Date: 2016-12-16 Interventions: Genetic: SPK-8011 A novel, bio-engineered, recombinant adeno-associated viral vector carrying human fact |
Terminated |
Study Name: Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A Condition: Hemophilia A Date: 2011-09-13 Interventions: Biological: OBI-1 intravenous infusion, up to every 2-3 hours for the first 24 hours of treatment |
Completed |
Study Name: Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A Condition: Hemophilia A Date: 2010-08-06 Interventions: Biological: OBI-1 Intravenous infusion |
Withdrawn |
Study Name: Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B Condition: Hemophilia B Date: 2013-11-14 Interventions: Biological: IB1001 Prophylaxis (during Treatment and Conti |
Completed |
Study Name: BAY14-2222 Prophylaxis and Joint Function Improvement (Adults) Condition:
Date: 2007-12-21 Interventions: Drug: Kogenate (BAY14-2222) One group two treatment schedules, first on-demand then switch to prophylaxi |